Circulating tumor cells are significantly useful in determining the status of disease progression rate and projection of therapy needed for tumor eradication. Further development of various tumor markers that can be used along with companion diagnostics to diagnose or monitor various forms of cancer are expected to boost usage rates of CTC tests in the coming years.
Circulating tumor cell detection test possesses the ability to detect, quantify, and analyze tumor cells in the blood of cancer patients. It includes enrichment, detection and analysis of the detected circulating tumor cells. Circulating tumor cells tests are applicable in the characterization of tumor cells through biochemical marker analysis. CTC isolation, detection, and molecular characterization systems find investigational application in prostate, breast, colon, head, neck, skin, lung, and pancreatic cancer
Growing incidences oncology diseases and the introduction of novel biotechnological methods that enable the isolation and quantitation of circulating tumor cells. Furthermore, other factors like early disease diagnosis, cost savings on multiple treatments, drug safety, patient compliance, and optimization of therapies are attributive for rising demand for the preventive medicine, thus influencing the demand for CTC tests.
On course of the forecast period it is expected that over 150 companion diagnostic on-label combinations and a range of personalized therapeutic drugs under clinical trials and development pipelines based on companion diagnostics. The level of adoption of companion diagnostics is expected to significantly increase after these obtain complete FDA approval and are commercialized fully.
Highlights
The global Circulating Tumor Cell Diagnostics market was valued at US$ 5449.1 million in 2022 and is anticipated to reach US$ 9239.7 million by 2029, witnessing a CAGR of 9.2% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Circulating Tumor Cell Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Circulating Tumor Cell Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Circulating Tumor Cell Diagnostics in Tumorigenesis research is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Circulating Tumor Cell Diagnostics include Janssen Diagnostics, Advanced Cell Diagnostics, Aviva Biosciences, Biocept Inc, Biofluidica Inc., CellTraffix Inc., Clearbridge BioMedics Pte Ltd, Epic Sciences Inc. and Fluxion Biosciences Inc., etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Circulating Tumor Cell Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor Cell Diagnostics.
The Circulating Tumor Cell Diagnostics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Circulating Tumor Cell Diagnostics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Circulating Tumor Cell Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Janssen Diagnostics
Advanced Cell Diagnostics
Aviva Biosciences
Biocept Inc
Biofluidica Inc.
CellTraffix Inc.
Clearbridge BioMedics Pte Ltd
Epic Sciences Inc.
Fluxion Biosciences Inc.
ScreenCell
Silicon Biosystems
Sysmex Corporation
Greiner Bio-One GmbH
AdnaGen AG
Apocell Inc
Biocep Ltd
Canopus Bioscience Ltd
Creatv Microtech Inc
Ikonisys Inc
IV Diagnostics Inc
Miltenyi Biotech GmbH
Nanostring Technologies Inc
Rarecells Diagnostics.
Vitatex Inc
Segment by Type
CTC Enrichment
CTC Detection
CTC Analysis
Segment by Application
Tumorigenesis research
EMT biomarkers development
Cancer stem cell research
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Circulating Tumor Cell Diagnostics companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Circulating Tumor Cell Diagnostics 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 CTC Enrichment
1.2.3 CTC Detection
1.2.4 CTC Analysis
1.3 麻豆原创 by Application
1.3.1 Global Circulating Tumor Cell Diagnostics 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Tumorigenesis research
1.3.3 EMT biomarkers development
1.3.4 Cancer stem cell research
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Circulating Tumor Cell Diagnostics 麻豆原创 Perspective (2018-2029)
2.2 Circulating Tumor Cell Diagnostics Growth Trends by Region
2.2.1 Global Circulating Tumor Cell Diagnostics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Circulating Tumor Cell Diagnostics Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Circulating Tumor Cell Diagnostics Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Circulating Tumor Cell Diagnostics 麻豆原创 Dynamics
2.3.1 Circulating Tumor Cell Diagnostics Industry Trends
2.3.2 Circulating Tumor Cell Diagnostics 麻豆原创 Drivers
2.3.3 Circulating Tumor Cell Diagnostics 麻豆原创 Challenges
2.3.4 Circulating Tumor Cell Diagnostics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Circulating Tumor Cell Diagnostics Players by Revenue
3.1.1 Global Top Circulating Tumor Cell Diagnostics Players by Revenue (2018-2023)
3.1.2 Global Circulating Tumor Cell Diagnostics Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Circulating Tumor Cell Diagnostics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Circulating Tumor Cell Diagnostics Revenue
3.4 Global Circulating Tumor Cell Diagnostics 麻豆原创 Concentration Ratio
3.4.1 Global Circulating Tumor Cell Diagnostics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Circulating Tumor Cell Diagnostics Revenue in 2022
3.5 Circulating Tumor Cell Diagnostics Key Players Head office and Area Served
3.6 Key Players Circulating Tumor Cell Diagnostics Product Solution and Service
3.7 Date of Enter into Circulating Tumor Cell Diagnostics 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Circulating Tumor Cell Diagnostics Breakdown Data by Type
4.1 Global Circulating Tumor Cell Diagnostics Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Circulating Tumor Cell Diagnostics Forecasted 麻豆原创 Size by Type (2024-2029)
5 Circulating Tumor Cell Diagnostics Breakdown Data by Application
5.1 Global Circulating Tumor Cell Diagnostics Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Circulating Tumor Cell Diagnostics Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Circulating Tumor Cell Diagnostics 麻豆原创 Size (2018-2029)
6.2 North America Circulating Tumor Cell Diagnostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Country (2018-2023)
6.4 North America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Circulating Tumor Cell Diagnostics 麻豆原创 Size (2018-2029)
7.2 Europe Circulating Tumor Cell Diagnostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Circulating Tumor Cell Diagnostics 麻豆原创 Size by Country (2018-2023)
7.4 Europe Circulating Tumor Cell Diagnostics 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Circulating Tumor Cell Diagnostics 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Circulating Tumor Cell Diagnostics 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Circulating Tumor Cell Diagnostics 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Circulating Tumor Cell Diagnostics 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Circulating Tumor Cell Diagnostics 麻豆原创 Size (2018-2029)
9.2 Latin America Circulating Tumor Cell Diagnostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Circulating Tumor Cell Diagnostics 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Circulating Tumor Cell Diagnostics 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Circulating Tumor Cell Diagnostics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Circulating Tumor Cell Diagnostics 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Circulating Tumor Cell Diagnostics 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Janssen Diagnostics
11.1.1 Janssen Diagnostics Company Detail
11.1.2 Janssen Diagnostics Business Overview
11.1.3 Janssen Diagnostics Circulating Tumor Cell Diagnostics Introduction
11.1.4 Janssen Diagnostics Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.1.5 Janssen Diagnostics Recent Development
11.2 Advanced Cell Diagnostics
11.2.1 Advanced Cell Diagnostics Company Detail
11.2.2 Advanced Cell Diagnostics Business Overview
11.2.3 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Introduction
11.2.4 Advanced Cell Diagnostics Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.2.5 Advanced Cell Diagnostics Recent Development
11.3 Aviva Biosciences
11.3.1 Aviva Biosciences Company Detail
11.3.2 Aviva Biosciences Business Overview
11.3.3 Aviva Biosciences Circulating Tumor Cell Diagnostics Introduction
11.3.4 Aviva Biosciences Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.3.5 Aviva Biosciences Recent Development
11.4 Biocept Inc
11.4.1 Biocept Inc Company Detail
11.4.2 Biocept Inc Business Overview
11.4.3 Biocept Inc Circulating Tumor Cell Diagnostics Introduction
11.4.4 Biocept Inc Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.4.5 Biocept Inc Recent Development
11.5 Biofluidica Inc.
11.5.1 Biofluidica Inc. Company Detail
11.5.2 Biofluidica Inc. Business Overview
11.5.3 Biofluidica Inc. Circulating Tumor Cell Diagnostics Introduction
11.5.4 Biofluidica Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.5.5 Biofluidica Inc. Recent Development
11.6 CellTraffix Inc.
11.6.1 CellTraffix Inc. Company Detail
11.6.2 CellTraffix Inc. Business Overview
11.6.3 CellTraffix Inc. Circulating Tumor Cell Diagnostics Introduction
11.6.4 CellTraffix Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.6.5 CellTraffix Inc. Recent Development
11.7 Clearbridge BioMedics Pte Ltd
11.7.1 Clearbridge BioMedics Pte Ltd Company Detail
11.7.2 Clearbridge BioMedics Pte Ltd Business Overview
11.7.3 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Introduction
11.7.4 Clearbridge BioMedics Pte Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.7.5 Clearbridge BioMedics Pte Ltd Recent Development
11.8 Epic Sciences Inc.
11.8.1 Epic Sciences Inc. Company Detail
11.8.2 Epic Sciences Inc. Business Overview
11.8.3 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Introduction
11.8.4 Epic Sciences Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.8.5 Epic Sciences Inc. Recent Development
11.9 Fluxion Biosciences Inc.
11.9.1 Fluxion Biosciences Inc. Company Detail
11.9.2 Fluxion Biosciences Inc. Business Overview
11.9.3 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Introduction
11.9.4 Fluxion Biosciences Inc. Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.9.5 Fluxion Biosciences Inc. Recent Development
11.10 ScreenCell
11.10.1 ScreenCell Company Detail
11.10.2 ScreenCell Business Overview
11.10.3 ScreenCell Circulating Tumor Cell Diagnostics Introduction
11.10.4 ScreenCell Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.10.5 ScreenCell Recent Development
11.11 Silicon Biosystems
11.11.1 Silicon Biosystems Company Detail
11.11.2 Silicon Biosystems Business Overview
11.11.3 Silicon Biosystems Circulating Tumor Cell Diagnostics Introduction
11.11.4 Silicon Biosystems Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.11.5 Silicon Biosystems Recent Development
11.12 Sysmex Corporation
11.12.1 Sysmex Corporation Company Detail
11.12.2 Sysmex Corporation Business Overview
11.12.3 Sysmex Corporation Circulating Tumor Cell Diagnostics Introduction
11.12.4 Sysmex Corporation Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.12.5 Sysmex Corporation Recent Development
11.13 Greiner Bio-One GmbH
11.13.1 Greiner Bio-One GmbH Company Detail
11.13.2 Greiner Bio-One GmbH Business Overview
11.13.3 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Introduction
11.13.4 Greiner Bio-One GmbH Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.13.5 Greiner Bio-One GmbH Recent Development
11.14 AdnaGen AG
11.14.1 AdnaGen AG Company Detail
11.14.2 AdnaGen AG Business Overview
11.14.3 AdnaGen AG Circulating Tumor Cell Diagnostics Introduction
11.14.4 AdnaGen AG Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.14.5 AdnaGen AG Recent Development
11.15 Apocell Inc
11.15.1 Apocell Inc Company Detail
11.15.2 Apocell Inc Business Overview
11.15.3 Apocell Inc Circulating Tumor Cell Diagnostics Introduction
11.15.4 Apocell Inc Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.15.5 Apocell Inc Recent Development
11.16 Biocep Ltd
11.16.1 Biocep Ltd Company Detail
11.16.2 Biocep Ltd Business Overview
11.16.3 Biocep Ltd Circulating Tumor Cell Diagnostics Introduction
11.16.4 Biocep Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.16.5 Biocep Ltd Recent Development
11.17 Canopus Bioscience Ltd
11.17.1 Canopus Bioscience Ltd Company Detail
11.17.2 Canopus Bioscience Ltd Business Overview
11.17.3 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Introduction
11.17.4 Canopus Bioscience Ltd Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.17.5 Canopus Bioscience Ltd Recent Development
11.18 Creatv Microtech Inc
11.18.1 Creatv Microtech Inc Company Detail
11.18.2 Creatv Microtech Inc Business Overview
11.18.3 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Introduction
11.18.4 Creatv Microtech Inc Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.18.5 Creatv Microtech Inc Recent Development
11.19 Ikonisys Inc
11.19.1 Ikonisys Inc Company Detail
11.19.2 Ikonisys Inc Business Overview
11.19.3 Ikonisys Inc Circulating Tumor Cell Diagnostics Introduction
11.19.4 Ikonisys Inc Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.19.5 Ikonisys Inc Recent Development
11.20 IV Diagnostics Inc
11.20.1 IV Diagnostics Inc Company Detail
11.20.2 IV Diagnostics Inc Business Overview
11.20.3 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Introduction
11.20.4 IV Diagnostics Inc Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.20.5 IV Diagnostics Inc Recent Development
11.21 Miltenyi Biotech GmbH
11.21.1 Miltenyi Biotech GmbH Company Detail
11.21.2 Miltenyi Biotech GmbH Business Overview
11.21.3 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Introduction
11.21.4 Miltenyi Biotech GmbH Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.21.5 Miltenyi Biotech GmbH Recent Development
11.22 Nanostring Technologies Inc
11.22.1 Nanostring Technologies Inc Company Detail
11.22.2 Nanostring Technologies Inc Business Overview
11.22.3 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Introduction
11.22.4 Nanostring Technologies Inc Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.22.5 Nanostring Technologies Inc Recent Development
11.23 Rarecells Diagnostics.
11.23.1 Rarecells Diagnostics. Company Detail
11.23.2 Rarecells Diagnostics. Business Overview
11.23.3 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Introduction
11.23.4 Rarecells Diagnostics. Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.23.5 Rarecells Diagnostics. Recent Development
11.24 Vitatex Inc
11.24.1 Vitatex Inc Company Detail
11.24.2 Vitatex Inc Business Overview
11.24.3 Vitatex Inc Circulating Tumor Cell Diagnostics Introduction
11.24.4 Vitatex Inc Revenue in Circulating Tumor Cell Diagnostics Business (2018-2023)
11.24.5 Vitatex Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Janssen Diagnostics
Advanced Cell Diagnostics
Aviva Biosciences
Biocept Inc
Biofluidica Inc.
CellTraffix Inc.
Clearbridge BioMedics Pte Ltd
Epic Sciences Inc.
Fluxion Biosciences Inc.
ScreenCell
Silicon Biosystems
Sysmex Corporation
Greiner Bio-One GmbH
AdnaGen AG
Apocell Inc
Biocep Ltd
Canopus Bioscience Ltd
Creatv Microtech Inc
Ikonisys Inc
IV Diagnostics Inc
Miltenyi Biotech GmbH
Nanostring Technologies Inc
Rarecells Diagnostics.
Vitatex Inc
听
听
*If Applicable.
